Literature DB >> 7608910

Orally active beta-lactam inhibitors of human leukocyte elastase. 3. Stereospecific synthesis and structure-activity relationships for 3,3-dialkylazetidin-2-ones.

P E Finke1, S K Shah, D S Fletcher, B M Ashe, K A Brause, G O Chandler, P S Dellea, K M Hand, A L Maycock, D G Osinga.   

Abstract

The stereospecific synthesis of several 4-[(4-carboxyphenyl)oxy]- 3,3-dialkyl-1-[[(1-phenylalkyl)-amino]carbonyl]azetidin-2-on es 3 is described in which the C-3 alkyl groups were varied from methyl to butyl as well as allyl, benzyl and methoxymethyl. The structure-activity relations for these compounds are discussed in terms of the hydrolytic stability of the beta-lactam ring, their in vitro inhibitory potency for human leukocyte elastase (HLE), and their in vivo oral efficacy in an HLE-mediated hamster lung hemorrhage assay. Further alkyl substitution on the benzylic urea moiety, especially in the R configuration, afforded enhanced HLE inhibition and in vivo efficacy. The stereochemical assignments for (3R,4S)-4-[(4-carboxyphenyl)oxy]-3-ethyl-3-methyl-1-[[((R)-1- phenylpropyl)amino]carbonyl]azetidin-2-one (42a) (kobs/[I] = 91,000 M-1 s-1) were confirmed with an X-ray structure determination, which was also utilized to develop an HLE inhibition model.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7608910     DOI: 10.1021/jm00013a021

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  3 in total

1.  Novel yeast cell-based assay to screen for inhibitors of human cytomegalovirus protease in a high-throughput format.

Authors:  Valérie Cottier; Alcide Barberis; Urs Lüthi
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

Review 2.  Current and potential treatments for ubiquitous but neglected herpesvirus infections.

Authors:  Jonathan E Gable; Timothy M Acker; Charles S Craik
Journal:  Chem Rev       Date:  2014-10-02       Impact factor: 60.622

3.  Mild deprotection of the N-tert-butyloxycarbonyl (N-Boc) group using oxalyl chloride.

Authors:  Nathaniel George; Samuel Ofori; Sean Parkin; Samuel G Awuah
Journal:  RSC Adv       Date:  2020-06-23       Impact factor: 4.036

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.